|
US6184201B1
(en)
|
1995-04-14 |
2001-02-06 |
Nps Allelix Corp. |
Intestinotrophic glucagon-like peptide-2 analogs
|
|
US5834428A
(en)
|
1995-04-14 |
1998-11-10 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
|
DK1231219T3
(da)
|
1996-04-12 |
2010-12-20 |
Ontario Inc 1149336 |
GLucagon-lignende peptid-2 analoger
|
|
US20020025933A1
(en)
*
|
1996-08-30 |
2002-02-28 |
Knudsen Liselotte Bjerre |
GLP-2 derivatives
|
|
CA2236519C
(en)
*
|
1997-05-02 |
2011-09-13 |
1149336 Ontario Inc. |
Methods of enhancing functioning of the large intestine
|
|
SE9802080D0
(sv)
*
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
|
KR20050037004A
(ko)
|
1998-12-07 |
2005-04-20 |
소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. |
Ｇｌｐ-1의 유사체
|
|
GB9930882D0
(en)
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
|
JP5161412B2
(ja)
|
2000-09-18 |
2013-03-13 |
サノス・バイオサイエンス・アクティーゼルスカブ |
Ｇｌｐ−１及びｇｌｐ−２ペプチドの使用方法
|
|
US20080249016A1
(en)
*
|
2000-09-18 |
2008-10-09 |
Sanos Bioscience A/S |
Use of GLP-2 in a combination treatment for bone-related disorders
|
|
US20070135345A1
(en)
*
|
2000-09-18 |
2007-06-14 |
Henriksen Dennis B |
Use of GLP-2 for the treatment or prevention, of bone-related disorders
|
|
US7371721B2
(en)
*
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
|
DE60226702D1
(de)
*
|
2001-02-16 |
2008-07-03 |
Conjuchem Biotechnologies Inc |
Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
|
|
US7411039B2
(en)
*
|
2002-10-14 |
2008-08-12 |
Novo Nordisk A/S |
GLP-2 compounds, formulations, and uses thereof
|
|
EP1592471B1
(en)
|
2003-02-04 |
2011-03-23 |
Novo Nordisk A/S |
Injection device with rotatable dose setting mechanism
|
|
EP1608680A2
(en)
*
|
2003-03-24 |
2005-12-28 |
Novo Nordisk A/S |
Glp-2 derivatives
|
|
WO2004103390A2
(en)
|
2003-05-15 |
2004-12-02 |
Trustees Of Tufts College |
Stable analogs of peptide and polypeptide therapeutics
|
|
ES2393335T3
(es)
|
2003-12-16 |
2012-12-20 |
Ipsen Pharma |
Análogos de GLP-1
|
|
EP2368579A1
(en)
|
2004-01-21 |
2011-09-28 |
Novo Nordisk Health Care AG |
Transglutaminase mediated conjugation of peptides
|
|
ES2427150T3
(es)
|
2004-11-01 |
2013-10-29 |
Nps Pharmaceuticals, Inc. |
Tratamiento de pacientes con el síndrome del intestino corto con colon en continuidad
|
|
PT1877435E
(pt)
|
2005-05-04 |
2011-05-24 |
Zealand Pharma As |
An?logos de p?ptido-2 semelhante a glucagon
|
|
WO2007119101A2
(en)
|
2005-12-01 |
2007-10-25 |
Nps Allelix Corp. |
Assay system for glp-2 receptor ligands
|
|
EP2051995B1
(en)
*
|
2006-11-08 |
2017-02-08 |
Zealand Pharma A/S |
Selective glucagon-like-peptide-2 (glp-2) analogues
|
|
EP2314616A1
(en)
*
|
2009-10-23 |
2011-04-27 |
Ferring B.V. |
Peptidic GLP-2 agonists
|
|
BR112013008957A2
(pt)
|
2010-10-15 |
2019-09-24 |
Univ Cornell |
composições e métodos para tratamento de doenças endócrinas, gastrointestinais ou autoimunes
|
|
CN102924589B
(zh)
*
|
2011-08-11 |
2016-08-24 |
中肽生化有限公司 |
胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
|
|
WO2013040093A2
(en)
|
2011-09-12 |
2013-03-21 |
Amunix Operating Inc. |
Glucagon-like peptide-2 compositions and methods of making and using same
|
|
PE20142451A1
(es)
|
2012-02-27 |
2015-02-04 |
Amunix Operating Inc |
Composiciones de conjugados de xten y metodos para realizar las mismas
|
|
EP2844670B1
(en)
|
2012-05-03 |
2017-12-06 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (glp-2) analogues
|
|
EP4424320A3
(en)
|
2016-12-09 |
2025-06-11 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
WO2018229252A1
(en)
|
2017-06-16 |
2018-12-20 |
Zealand Pharma A/S |
Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
|
|
WO2020020904A1
(en)
|
2018-07-23 |
2020-01-30 |
Zealand Pharma A/S |
Therapeutic uses of glp-2 agonists
|